Popular OTC drugs can slow down the spread of breast, intestinal and prostate cancer

The rate of breast cancer is increasing for women under 40 in the US, with recent research showing that they have grown by more than 0.5% per year in 21 countries.

Moreover, the level of prostate cancer has increased by 2% to 3% per year, and the level of colon cancer increased by 1% to 2% per year among individuals younger than 55, data show.

Now, a new study has identified a popular drug as a potential agent in slowing the progress of certain cancers – including those of the breast, intestine and prostate – and the best part is that it is available above the counter.

Aspirin can help the immune system fight widespread cancer by blocking a chemical (TXA2), made of blood platelets, which would otherwise weaken the body’s T cells, which are important for attacking cancer cells, found study.

Previous research has shown that aspirin has the potential to slow down some cancers.

A 2021 analysis that examined 13 studies with over 140,000 patients with breast cancer found that the use of aspirin was linked to a 31% decrease in specific breast cancer mortality and a 9% reduction in the risk of recurrence or metastasis.

Regular use of aspirin was also associated with a decrease in more than 25% of the risk of colon cancer in a 2020 analysis.

However, exactly how aspirin seemed to slow down the spread was unclear – so far.

The new findings, published Wednesday in Nature magazine, could have extensive implications, especially as 90% of cancer deaths occur when cancer spreads throughout the body.

“Most immunotherapists have developed to treat patients with metastatic cancer set, but when cancer is spread for the first time, there is a unique window of therapeutic possibilities when cancer cells are particularly vulnerable to immune attack,” the author of Rahul Roychoudhuri, a professor of cancer immunology at the University of Cancer, said.

“Hopefully the therapies aimed at this window of vulnerability will have a tremendous space in preventing recurrence in patients with early cancer at risk of recurrence.”

This can mean more cost -effective and accessible treatment options for people with early stages of cancer.

“Aspirin, or other medicines that may aim for this route, have the potential to be less expensive than antibodies based on therapies, and therefore more globally accessible,” said co -author Dr. Jie Yang.

UK professor Ruth Langley, who is leading the additional clinical test of aspirin but not included in this study, said this was “an important discovery [that] It will enable us to interpret the results of the ongoing clinical tests and work who is most likely to benefit from aspirin after a diagnosis of cancer. “

If you are thinking of adding aspirin to your daily routine, first check with your doctor. The pill is not for everyone.